Fact-checked by Grok 2 weeks ago

Risdiplam

Risdiplam, sold under the brand name Evrysdi, is a small-molecule survival 2 (SMN2) splicing modifier used to treat (SMA), a rare genetic neuromuscular disorder caused by mutations in the that lead to insufficient SMN protein production. By promoting the inclusion of 7 in SMN2 mRNA transcripts, risdiplam increases systemic levels of full-length SMN protein, addressing the underlying cause of SMA and improving motor function in affected patients. Approved by the U.S. (FDA) in August 2020 for patients two months of age and older, it represents the first oral, at-home SMA therapy, available as a powder for oral solution or, since February 2025, a dispersible tablet for individuals aged two years and older weighing more than 44 pounds. Developed collaboratively by , the Foundation, and /, risdiplam received designation from the FDA in 2017 and from the in 2019, followed by FDA status in 2019, accelerating its path to approval based on promising early clinical data. The drug's efficacy was demonstrated in pivotal phase 3 trials, including FIREFISH for infantile-onset (type 1) and for later-onset (types 2 and 3) . In FIREFISH, 29% of treated infants achieved the ability to sit without support for at least five seconds after 12 months, compared to 0% in historical controls, with 85% event-free survival (no death or permanent ventilation). In , patients receiving risdiplam showed a statistically significant 1.36-point improvement in the Motor Function Measure-32 (MFM-32) scale after , versus a 0.19-point decline in the group, indicating sustained motor benefits over 24 months. Risdiplam is administered once daily after a , with dosing weight- and age-based: 0.15 / for infants under two months, up to a fixed 5 for adults and children over 20 . Common adverse effects include fever, , , and respiratory infections, particularly in younger patients, though serious events like occur in a minority. Ongoing studies, such as JEWELFISH and , continue to evaluate its safety and effectiveness in broader populations, including those previously treated with other therapies like or , confirming stable or improved motor outcomes with long-term use up to 30 months. As of 2025, risdiplam remains a cornerstone of management, offering a noninvasive alternative that enhances accessibility for lifelong .

Medical uses

Indications

Risdiplam is indicated for the treatment of () in pediatric and adult patients of all ages, including those with types 1, 2, and 3 disease. This approval covers symptomatic patients across these subtypes, where risdiplam addresses the underlying genetic defect by enhancing survival motor neuron (SMN) protein production. The indication was extended in to include infants under 2 months of age based on interim data from the trial, which demonstrated significant motor and survival benefits in presymptomatic infants; full results were published in 2025. This expansion supports early intervention through programs, allowing treatment initiation before symptom onset in infants with confirmed biallelic mutations. In adults with 5q-SMA, risdiplam is utilized, as evidenced by a 2025 observational published in eClinicalMedicine (). The study highlighted stable or improved motor function in treatment-naïve adults, underscoring its applicability in later-onset and advanced disease presentations. Investigational use of risdiplam in combination with gene therapies, such as , is being explored, with 2025 data showing feasibility and potential additive efficacy in post-gene therapy patients. As the first approved oral therapy for , risdiplam facilitates at-home , improving accessibility for patients across age groups.

Dosage and administration

Risdiplam is administered orally once daily, with dosing determined by the patient's age and body weight. For infants younger than 2 months of age, the recommended dose is 0.15 mg/kg body weight using the oral . For children aged 2 months to less than 2 years, the dose is 0.2 mg/kg body weight, also via oral . In patients 2 years and older weighing less than 20 kg, the dose is 0.25 mg/kg body weight with the oral . For those 2 years and older weighing 20 kg or more, a fixed dose of 5 mg is used, which may be given as either the oral or the tablet approved by the FDA in February 2025.
Age GroupBody WeightRecommended DoseFormulation
< 2 monthsAll0.15 mg/kg once dailyOral solution
2 months to < 2 yearsAll0.2 mg/kg once dailyOral solution
≥ 2 years< 20 kg0.25 mg/kg once dailyOral solution
≥ 2 years≥ 20 kg5 mg once dailyOral solution or tablet
The oral solution is provided as a powder that must be constituted by a healthcare provider by adding 79 mL of purified water to the 60 mg bottle, yielding a concentration of 0.75 mg/mL; the constituted solution should be shaken well before each use. It is drawn up using the provided oral syringe and administered immediately (within 5 minutes) to prevent degradation, followed by water to ensure complete swallowing; it should not be mixed with breast milk, formula, or any other liquids or foods. For infants, administration occurs after breastfeeding. The solution may also be given via nasogastric or gastrostomy tube, followed by a water flush. Tablets, intended for patients able to swallow them, are taken whole with water or dispersed in 5 mL of non-chlorinated water (such as filtered water) and consumed within 10 minutes; after consuming the dispersion, add 15 mL of non-chlorinated water to the cup, swirl gently, and consume immediately to ensure the full dose; they are not suitable for tube administration. Dosing should occur at the same time each day, preferably after a meal for the oral solution or with or without food for tablets. If a dose is missed, it should be taken if remembered within 6 hours; otherwise, skip it and resume the regular schedule without doubling the next dose. Doses based on body weight require recalculation if the patient's weight changes significantly, using the provided dosing tools or calculator for accuracy. No dose adjustment is necessary for mild or moderate hepatic impairment (Child-Pugh Class A or B), as risdiplam exposure is not meaningfully altered; however, use in severe hepatic impairment (Child-Pugh Class C) has not been studied and is not recommended. The dry powder for oral solution is stored at controlled room temperature (20°C to 25°C, excursions permitted to 15°C to 30°C), while the constituted solution is refrigerated upright at 2°C to 8°C (36°F to 46°F) and protected from light, with a discard date of 64 days after constitution or after 5 cumulative days at room temperature up to 40°C (104°F). Tablets are stored at 20°C to 25°C (68°F to 77°F) in their original packaging to protect from moisture. During preparation, healthcare providers should wear gloves to avoid skin contact, inhalation, or exposure to mucous membranes, and wash thoroughly if contact occurs. Any unused constituted solution beyond the expiration should be discarded per local regulations.

Pharmacology

Mechanism of action

Risdiplam is a small-molecule survival motor neuron 2 (SMN2) splicing modifier that promotes the inclusion of exon 7 in SMN2 pre-mRNA transcripts. It achieves this by binding to two specific sites in the SMN2 pre-mRNA: the exonic splicing enhancer 2 (ESE2) within exon 7 and the 5' splice site of intron 7. This binding stabilizes the interaction between the pre-mRNA and U1 small nuclear ribonucleoprotein (snRNP), enhancing recognition of the splice sites and favoring the production of full-length SMN2 mRNA over the truncated isoform that lacks exon 7. As a result, risdiplam increases the levels of functional SMN protein, which is essential for motor neuron survival. In spinal muscular atrophy (SMA), mutations in the SMN1 gene lead to deficient production of functional SMN protein, while individuals typically retain multiple copies of the that provide partial compensatory expression. Risdiplam compensates for the SMN1 loss by amplifying SMN protein production from these SMN2 copies, thereby addressing the underlying genetic defect at the molecular level. The drug's effects are systemic, elevating SMN protein levels throughout the body, including in the central nervous system (), due to its ability to cross the blood-brain barrier. As an orally administered small molecule, risdiplam offers a non-invasive alternative to intrathecal delivery methods for SMA therapies, enabling broad tissue distribution without invasive procedures. Preclinical studies in transgenic mouse models of SMA have demonstrated that oral dosing with risdiplam leads to dose-dependent increases in full-length SMN protein in both CNS and peripheral tissues, such as brain and muscle, confirming its potential to restore SMN levels in affected models.

Pharmacokinetics

Risdiplam exhibits linear pharmacokinetics across the dose range of 0.02 to 0.25 mg/kg once daily in patients with spinal muscular atrophy (SMA) and 0.6 to 18 mg in healthy adults. Steady-state concentrations are achieved within 7 to 14 days of daily oral administration, accompanied by approximately threefold accumulation in both peak concentration (Cmax) and the 24-hour area under the concentration-time curve (0-24h). The absolute oral is estimated at approximately 81%.

Absorption

Risdiplam is rapidly absorbed after , with a time to maximum concentration (Tmax) of 3.3 to 4 hours in the fasted state; administration in the fed state delays Tmax by up to 1 hour but does not alter overall exposure. A high-fat, high-calorie has no clinically relevant effect on risdiplam , Cmax, or , supporting flexible dosing with or without food. Both the oral solution and tablet formulations demonstrate comparable bioavailability under fasted and fed conditions.

Distribution

The apparent at is 190 L (approximately 6 L/kg) in a representative 31.3 kg , reflecting extensive distribution including penetration into the via crossing of the blood-brain barrier, as demonstrated in preclinical animal models. Risdiplam is 89% bound to proteins, predominantly , resulting in a free fraction of 11%; it shows no binding to alpha-1 acid glycoprotein.

Metabolism

Hepatic metabolism represents the primary route of for risdiplam, primarily mediated by flavin-containing monooxygenases 1 and 3 (FMO1 and FMO3), with secondary contributions from enzymes , CYP2J2, , and CYP3A7. The unchanged parent drug constitutes 83% of total circulating drug-related material, while the major , M1, is pharmacologically inactive and accounts for the remainder; no active metabolites are formed.

Elimination

The terminal elimination half-life of risdiplam is approximately 50 hours in healthy adults, with an apparent oral clearance of 2.45 L/h in a 31.3 kg patient. After administration of a 18 mg radiolabeled dose, 53% of the radioactivity is recovered in feces (14% as unchanged risdiplam) and 28% in urine (8% unchanged), indicating mixed hepatobiliary and renal elimination pathways with limited unchanged drug excretion.

Special Populations

Pharmacokinetic parameters of risdiplam show no clinically meaningful differences based on race or sex. Mild or moderate hepatic impairment results in minor changes to exposure (AUC decreased by ~20% in mild cases and increased by ~8% in moderate cases versus healthy controls), necessitating no dose adjustment, while severe hepatic impairment remains unstudied. Given the low fraction of unchanged drug excreted renally (8%), no dosage modifications are required for renal impairment. In pediatric SMA patients, weight- and age-adjusted dosing yields exposures comparable to adults (mean AUC0-24h ~1900–2100 ng·h/mL across age groups from 1 month to 25 years), though pharmacokinetic data are unavailable for infants younger than 16 days.

Clinical efficacy

Key clinical trials

The FIREFISH trial was a Phase 2/3, open-label, multicenter study evaluating risdiplam in infants with infantile-onset (Type 1) (). It consisted of two parts: Part 1 was a dose-escalation study involving 21 infants aged 1 to 7 months, with primary endpoints of safety, , , and dose selection. Exploratory outcomes included survival without permanent at 12 months. Part 2 expanded to additional infants, focusing on motor function milestones, and contributed pivotal data supporting regulatory approvals for this population. The trial was a Phase 2/3 study designed to assess risdiplam in patients with later-onset (Types 2 and 3). It included a dose-finding Part 1 and a confirmatory Part 2, which was double-blind and placebo-controlled, enrolling 180 children and adults aged 2 to 25 years. The primary endpoint in Part 2 was the change from baseline in motor function measured by the Motor Function Measure-32 (MFM-32) scale after 12 months of treatment. The JEWELFISH trial was a Phase 2, open-label, exploratory study investigating the and of risdiplam in a broad population of previously treated patients. It enrolled 174 participants aged 1 month to 60 years across Types 1, 2, and 3 who had received prior therapies such as or , with the primary focus on , tolerability, and pharmacodynamic effects. The trial was a Phase 3, open-label, single-arm study targeting presymptomatic infants with genetically confirmed . It enrolled 26 infants under 6 weeks of age, with the primary endpoint evaluating the proportion able to sit independently for at least 5 seconds at 12 months. Updated 2025 data from this trial demonstrated that 92% of participants (24/26) achieved sitting without support for at least 5 seconds at 12 months, with 81% (21/26) able to sit unsupported for 30 seconds, markedly exceeding expectations and supporting expanded use in neonates. Post-approval extension studies in 2025 provided evidence of risdiplam's efficacy in adults with 5q-associated . A nationwide observational in followed 57 treatment-naïve adults aged 16 years and older across eight centers, assessing motor function via Hammersmith Functional Motor Scale Expanded (HFMSE) and Revised Upper Limb Module (RULM) over at least 18 months, with results indicating stabilization or improvement in a majority of patients. Ongoing trials in 2025 have explored risdiplam in combination with for . A multicenter retrospective case series examined risdiplam administration following in 20 pediatric patients (primarily Type 1 ), reporting no serious adverse events and motor function stability or gains in 92% of assessable cases, informing potential sequential therapy strategies.

Outcomes across SMA types

In infantile-onset ( Type 1), risdiplam treatment in the FIREFISH trial demonstrated 85% event-free survival (defined as alive without permanent ) at 12 months, a marked improvement over historical controls where fewer than 26% achieved this outcome. Motor milestones were also notably advanced, with 29% of treated infants achieving the ability to sit without support for at least 5 seconds by 12 months, compared to none in untreated historical cohorts. For later-onset SMA (Types 2 and 3), the SUNFISH trial showed a mean +1.6-point improvement from baseline on the Motor Function Measure-32 (MFM-32) scale at 12 months in patients aged 2–25 years, versus no change in the placebo group, indicating stabilization or gains in motor function such as standing and reaching. This improvement was clinically meaningful, with 58% of patients showing stabilization and 32% exhibiting gains on the MFM-32 at 24 months, supporting risdiplam's role in preserving upper and lower limb function across ambulatory and non-ambulatory subgroups. In presymptomatic , 2025 data from the trial revealed near-normal developmental trajectories, with 81% of infants achieving independent walking by 18 months when treated early (within 6 weeks of birth), far exceeding expectations where most with 2 SMN2 copies would develop symptoms by 6 months. At 12 months, 81% could sit unsupported for 30 seconds and 42% walked independently, highlighting risdiplam's potential to enable typical motor progression in this population. Among adults with , 2025 observational studies reported improved Hammersmith Functional Motor Scale Expanded (HFMSE) scores, with mean increases of 2.5 points from baseline after 12 months, particularly benefiting non-ambulatory patients by enhancing function and reducing scoliosis-related limitations through better trunk stability. Clinically meaningful gains (≥3 points on HFMSE) occurred in 64% of treated adults, sustaining respiratory and daily activity independence.00469-9/fulltext) Long-term data up to 3 years across trials like FIREFISH and confirm sustained increases in SMN protein levels (approximately twofold from baseline) and motor gains, such as continued MFM-32 improvements and milestone retention, demonstrating disease-modifying effects without curative resolution. These outcomes reflect risdiplam's ongoing impact on progression, with 88% event-free survival in Type 1 at 24 months and motor stabilization in Types 2/3, though benefits plateau in advanced disease stages.

Adverse effects

Common adverse effects

The most common adverse effects of risdiplam, occurring in more than 10% of patients across clinical trials, include fever, , , upper infections, , and . In patients with later-onset (SMA), fever was reported in 22%, diarrhea in 17%, and rash in 17% of treated individuals, with these rates exceeding those in groups. For infantile-onset SMA, additional frequent effects encompassed upper infections (≥10%), lower respiratory tract infections (≥10%), (≥10%), and the aforementioned gastrointestinal and dermatological issues. Incidence rates vary by age group, with infants and younger pediatric patients experiencing higher rates of infections, such as upper infections reaching up to 82% in some cohorts, compared to adults where gastrointestinal effects like predominate at around 20%. These effects are generally mild to moderate and managed through , with most resolving without necessitating treatment discontinuation. As of 2025, post-approval safety data from expanded populations, including long-term studies and real-world use, confirm no new common adverse effects beyond those identified in initial trials, maintaining the established tolerability profile.

Serious adverse effects

Serious adverse effects associated with risdiplam occur infrequently and are often attributable to the underlying () rather than the drug itself, with respiratory complications being the most prominent in infantile-onset cases. In pivotal clinical trials such as FIREFISH and , serious adverse events were reported in 44% of participants overall, but risdiplam-related serious events were limited, primarily consisting of (incidence of 8% in treated patients versus 2% in controls), (2%), and bacteremia (2%). These events were more common in infants with type 1 due to disease-related vulnerability, and no deaths were attributed to risdiplam. Post-marketing data from the FDA Reporting System (FAERS) between 2020 and 2023 identified 703 serious among 1,588 total reports for risdiplam, representing about 44% of cases; however, was not always established. A potential signal emerged for elevated hepatic s (hepatic enzyme increased), with 11 reports yielding a reporting (ROR) of 2.84 (95% : 1.57–5.14), suggesting a disproportionate association compared to other drugs, though no instances of clinically significant or grade 3/4 elevations leading to discontinuation were noted in pre-approval trials. Baseline and periodic monitoring of (/) is not mandated in the prescribing information but may be considered in patients with risk factors, given the post-marketing signal. Preclinical nonclinical studies indicated potential carcinogenicity, with risdiplam causing an increased incidence of squamous cell carcinomas in male rats and adenomas/carcinomas in female rats at exposures approximating the human maximum recommended dose (5 mg/day); however, no carcinogenic effects were observed in Tg.rasH2 mice, and no human cases have been reported to date. The carcinogenic potential in humans remains unevaluated. In , risdiplam is not assigned a formal category, but animal studies demonstrated embryo-fetal , including skeletal variations and reduced fetal weight, at doses below exposure; thus, it may cause fetal harm. testing is recommended prior to treatment initiation in females of reproductive potential, with effective contraception advised during and for at least 1 month after the last dose. A registry is available for monitoring outcomes (1-833-760-1098 or https://www.evrysdipregnancyregistry.com).[](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/219285s000lbl.pdf) As of 2025, long-term safety data confirm risdiplam's favorable profile, with no new signals in expanded populations. In combination therapy following (n=14), risdiplam was well-tolerated without additional safety concerns. Similarly, the phase 3 trial in presymptomatic infants (up to 6 weeks old) reported a safety profile consistent with prior studies, including no treatment-related serious adverse events beyond expected SMA-related issues, supporting its use across age groups including adults.

History

Development

Risdiplam was discovered in the through a collaboration between and the SMA Foundation, utilizing to identify small molecules that modulate SMN2 splicing to increase functional SMN protein production in (). Preclinical studies demonstrated proof-of-concept in SMA mouse models, such as the severe C/C-allele and Δ7 models, where risdiplam restored SMN protein levels in the (up to 206% of wild-type) and quadriceps muscle (up to 241% of wild-type) at doses of 1–3 mg/kg, while extending median survival from 10.5 days in untreated mice to 26 days at 0.1 mg/kg oral dosing. These models also showed improvements in neuromuscular and reduced with daily dosing from postnatal day 3. In 2011, entered a partnership with for the global development of SMN2 splicing modifiers, including risdiplam (initially RG7916), providing upfront payments and milestones to advance the program. The compound received designation from both the FDA and in 2017 to support its development for . Early development efforts addressed challenges in achieving optimal oral and penetration, with risdiplam optimized as a small-molecule splicing modifier exhibiting high oral (>80%) and brain to enable systemic SMN elevation. Key milestones included the initiation of the first-in-human phase 1 trial (NCT02633709) in January 2016 to assess , tolerability, and in healthy volunteers. Prior to regulatory approval, an program (NCT04256265) was launched in 2020 to provide risdiplam to eligible patients with type 1 or 2 who had no other treatment options.

Regulatory approvals

Risdiplam, marketed as Evrysdi, received its initial approval from the U.S. (FDA) on August 7, 2020, for the treatment of () in patients two months of age and older, regardless of disease type or severity. This approval was based on accelerated pathways, including and designation, following positive interim data from the FIREFISH and SUNFISH clinical trials. The FDA expanded the label on May 31, 2022, to include infants under two months of age with , supported by interim results from the study demonstrating efficacy in presymptomatic infants. In February 2025, the FDA approved a new tablet of risdiplam for patients two years and older weighing more than 20 kg, providing an alternative to the oral solution for improved administration convenience; this update also included revised prescribing information on dosing and storage. The () granted marketing authorization for risdiplam on March 26, 2021, for the treatment of 5q in patients two months of age and older, encompassing all disease types and severities across pediatric and adult populations. This approval followed a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) and was granted under the centralized procedure, valid throughout the . In , risdiplam was approved by the Ministry of Health, Labour and Welfare on June 23, 2021, for patients with aged two months and older, marking it as the first oral therapy available in the country for this indication. Similarly, China's approved risdiplam in June 2021 for the treatment of in patients two months and older. New real-world data published in September 2025 from an Austrian supported broader use in adults with 5q , confirming sustained safety and efficacy profiles that reinforced existing indications without requiring further regulatory changes. Compassionate use programs, initiated globally in late 2019 to provide access prior to approvals, largely transitioned to standard commercial availability following these regulatory milestones, though some continued in select regions as of 2023. As part of post-marketing commitments, and partners are conducting long-term safety studies, including a non-interventional post-authorisation efficacy study for ongoing in real-world settings and the Risdiplam Single-Arm Pregnancy Safety Study to monitor outcomes in pregnant individuals. A proposal for inclusion of risdiplam on the WHO Model List of was submitted in November 2024 but was not included following review in , despite aims to facilitate access in low- and middle-income countries.

Society and culture

Risdiplam is classified as a prescription-only medication worldwide and is not designated as a controlled substance under any international or national drug scheduling systems. Its availability is regulated through standard pharmaceutical approval processes, requiring initiation and oversight by physicians experienced in treating spinal muscular atrophy (SMA). The drug has received regulatory approval in over 100 countries, including the (FDA approval in August 2020), the (EMA authorization in March 2021), (initial approval in 2020 with tablet formulation in March 2025), , and . Despite this broad approval, access remains restricted in low- and middle-income countries, where high pricing and limited reimbursement hinder widespread use. In October 2025, India's upheld the launch of a generic version by at a 97% compared to the branded product, potentially improving affordability for patients in the country. In September 2025, the rejected risdiplam's inclusion on the Model List of , citing affordability concerns despite its clinical benefits for . In the United States, risdiplam's annual is weight-based, approximately $100,000 for infants under 2 years old and up to $340,000 for adults, positioning it as a high-cost comparable to other treatments. , through its Genentech subsidiary, offers patient assistance programs such as the Evrysdi Co-pay Program and free medication for uninsured or underinsured eligible patients to address financial barriers. Most US commercial plans and cover risdiplam for patients, often with , achieving high reimbursement rates; however, out-of-pocket costs can still pose challenges without assistance. In emerging markets, insurance coverage is inconsistent and frequently inadequate, leading to significant access disparities and reliance on negotiated lower prices in select countries like . A key development in 2025 was the European Commission's approval of a 5 mg tablet formulation in June, building on data from the trial that demonstrated efficacy in presymptomatic infants; this innovation simplifies administration for older children and adults, enhancing overall access across EU member states.

Names and access programs

Risdiplam is known by its (INN), with the chemical nomenclature 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one. It is marketed globally under the brand name Evrysdi by and its affiliates, including in the United States. Generic versions of risdiplam remain unavailable until expiry, projected around May 2035 for key composition-of-matter protections. Evrysdi is available in two oral formulations: an original powder for oral introduced in 2020, supplied as 60 mg/80 mL (0.75 mg/mL) for daily administration. In February 2025, a 5 mg tablet formulation was approved by the FDA as the first solid oral option for , suitable for patients aged 2 years and older weighing at least 20 kg, which can be swallowed whole or dispersed in water. Prior to regulatory approvals, provided to risdiplam from late 2019 through 2020 via a U.S. expanded access program for patients with Type 1 or 2 ineligible for clinical trials. This was complemented by a global compassionate use program launched in November 2019, which continues to offer access in regions without regulatory approval through named-patient programs managed by . These initiatives, the largest compassionate use effort for to date, have supported more than 18,000 patients worldwide in clinical, compassionate, and real-world settings as of June 2025. To address affordability, the Evrysdi Co-pay in the United States assists eligible commercially insured patients with out-of-pocket costs, providing up to $25,000 annually per prescription for FDA-approved uses. For uninsured or low-income patients, the Patient Foundation offers free Evrysdi to those meeting financial eligibility criteria. Globally, supports access for low- and middle-income countries through broader initiatives like the Global Access Program, though specific Evrysdi pricing assistance varies by region and is often integrated into local patient support services.

References

  1. [1]
    [PDF] EVRYSDI® (risdiplam) for oral solution - accessdata.fda.gov
    For more information, go to www.EVRYSDI.com or call 1-833-387-9734. This Patient Information has been approved by the U.S. Food and Drug Administration.
  2. [2]
    Risdiplam: Uses, Interactions, Mechanism of Action | DrugBank Online
    May 20, 2019 · Risdiplam is an mRNA splicing modifier for SMN2 that increases the inclusion of exon 7 during splicing, which ultimately increases the amount of ...Identification · Pharmacology · Interactions · References
  3. [3]
    FDA Approves Oral Treatment for Spinal Muscular Atrophy
    Aug 7, 2020 · The US Food and Drug Administration today approved Evrysdi (risdiplam) to treat patients two months of age and older with spinal muscular atrophy (SMA).
  4. [4]
    Press Releases | Wednesday, Feb 12, 2025 - Genentech
    Feb 12, 2025 · The US Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for an Evrysdi (risdiplam) tablet for people living with spinal muscular ...
  5. [5]
    FDA approves Roche's Evrysdi (risdiplam) for treatment of spinal ...
    Aug 10, 2020 · Risdiplam was granted PRIME designation by the European Medicines Agency (EMA) in 2018 and Orphan Drug Designation by FDA and EMA in 2017 and ...
  6. [6]
    Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy ...
    Jul 28, 2021 · In this study involving infants with type 1 SMA, risdiplam resulted in higher percentages of infants who met motor milestones and who showed ...
  7. [7]
    Safety Results in Previously-Treated SMA, Clinical Trial Results
    Find information about the clinical trial data from the JEWELFISH study of Evrysdi® (risdiplam) for patients with Type 1, 2, or 3 SMA.
  8. [8]
    Risdiplam in Adult Patients With 5q Spinal Muscular Atrophy: A ...
    Dec 26, 2024 · Discussion. Risdiplam treatment over 30 months resulted in overall CMI in most treated adult SMA type 2 or 3 patients. Outpatient drug ...<|separator|>
  9. [9]
    [PDF] EVRYSDI® (risdiplam) for oral solution - accessdata.fda.gov
    EVRYSDI is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. 2 DOSAGE AND ADMINISTRATION. 2.1 Dosing Information.
  10. [10]
    Risdiplam in Presymptomatic Spinal Muscular Atrophy - PubMed
    Aug 14, 2025 · The safety and efficacy of risdiplam in presymptomatic disease are unclear. Methods: We conducted an open-label study of daily oral risdiplam ( ...
  11. [11]
    Risdiplam treatment following onasemnogene abeparvovec in ... - NIH
    Jul 7, 2025 · Clinical efficacy and safety of risdiplam use as combination therapy in spinal muscular atrophy (SMA) patients post onasemnogene-abeparvovec- ...
  12. [12]
    PTC Therapeutics Announces FDA Approval of Evrysdi™ (risdiplam ...
    Aug 7, 2020 · Evrysdi represents the first at home, oral treatment approved for infants, children and adults with all SMA types.
  13. [13]
    [PDF] VRYSDI (risdiplam) tablets - accessdata.fda.gov
    Feb 11, 2025 · This NDA provides for the use of EVRYSDI (risdiplam) tablets for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.
  14. [14]
    [PDF] INSTRUCTIONS FOR USE EVRYSDI® [ev-RIZ-dee] (risdiplam) for ...
    Do not mix EVRYSDI into food or liquids. Do not mix EVRYSDI with formula or milk. • Do not take EVRYSDI if the bottle or oral syringes are damaged. • Avoid ...
  15. [15]
    Find Evrysdi® (risdiplam) Dosing Information | Official Healthcare ...
    This table is for reference only. The healthcare provider should calculate the correct dose according to the patient's body weight prior to administration.
  16. [16]
    Effect of mild or moderate hepatic impairment on the ... - PubMed
    Therefore, no dose adjustment is required in patients with mild or moderate hepatic impairment when receiving risdiplam.
  17. [17]
    Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 ...
    Jul 25, 2018 · mechanism of action is via stabilization of the transient double-strand RNA structure formed by the SMN2 pre-mRNA and U1 small nuclear ...Background · Compound Design and... · Conclusions · Supporting Information
  18. [18]
    Specificity, synergy, and mechanisms of splice-modifying drugs
    Feb 29, 2024 · Biochemical studies have shown that both risdiplam and branaplam bind to and stabilize the complex formed by the U1 snRNP and the 5' splice site ...Introduction · Results · Risdiplam And Branaplam...<|separator|>
  19. [19]
    Mechanism of Action | Evrysdi® (risdiplam)
    *Proposed mechanism of action. In preclinical studies, risdiplam was shown to increase exon 7 inclusion in SMN2 messenger ribonucleic acid (mRNA) transcripts ...
  20. [20]
    [PDF] Evrysdi, INN-risdiplam - European Medicines Agency
    Hepatic impairment. No dose adjustment is required in patients with mild or moderate hepatic impairment. Patients with severe hepatic impairment have not been ...
  21. [21]
    Risdiplam distributes and increases SMN protein in both the central ...
    Nov 29, 2018 · A parallel dose‐dependent increase in SMN protein levels was seen in CNS and peripheral tissues in two SMA mouse models dosed with risdiplam.
  22. [22]
    [PDF] 213535Orig1s000 CLINICAL PHARMACOLOGY REVIEW(S)
    Sep 24, 2019 · No dose adjustment is required for patients with renal impairment. Risdiplam is predominantly metabolized in the liver. Hepatic impairment may ...
  23. [23]
    [PDF] HIGHLIGHTS OF PRESCRIBING INFORMATION These ... - Genentech
    After administration of EVRYSDI as an oral solution, pharmacokinetics of risdiplam were approximately linear between 0.6 and 18 mg in a single-ascending-dose ...
  24. [24]
    Risdiplam in Type 1 Spinal Muscular Atrophy
    Feb 24, 2021 · In infants with type 1 spinal muscular atrophy, treatment with oral risdiplam led to an increased expression of functional SMN protein in the blood.
  25. [25]
    [PDF] 213535Orig1s000 CLINICAL REVIEW(S) - accessdata.fda.gov
    Jul 24, 2020 · Table 20: Summary of Firefish Efficacy Endpoints in Part 1 at Month 12 (ITT Population) ....... 84 ... Figure 4: Firefish Study Design ...
  26. [26]
    Two-year efficacy and safety of risdiplam in patients with type 2 or ...
    Feb 3, 2023 · A total of 180 patients were enrolled in SUNFISH Part 2 and were randomized to receive risdiplam (n = 120) or placebo (n = 60) for 12 months ( ...
  27. [27]
    JEWELFISH: 24-month results from an open-label study in non ...
    May 11, 2024 · The JEWELFISH study was designed to assess the safety, tolerability, pharmacokinetics (PK), and PK/pharmacodynamic (PD) relationship of risdiplam in non- ...
  28. [28]
  29. [29]
    Risdiplam treatment following onasemnogene abeparvovec in ...
    Jul 7, 2025 · NCT05861999: A study evaluating the effectiveness and safety of risdiplam administered in pediatric patients with spinal muscular atrophy who ...Patient Information · Dysphagia Changes After... · Ethics Approval And Consent...
  30. [30]
    Press Releases | Monday, Apr 27, 2020 - Genentech
    Apr 27, 2020 · FIREFISH Part 2 study met its primary endpoint by demonstrating a significant increase in motor milestones in infants aged 1-7 months after ...
  31. [31]
    Positive Data from FIREFISH Study of Evrysdi™ (risdiplam) in Infants ...
    Feb 24, 2021 · The median duration of treatment was 14.8 months at the time of analysis. The median age at enrollment was 6.7 months and symptom onset between ...
  32. [32]
    [PDF] 213535Orig1s000 SUMMARY REVIEW - accessdata.fda.gov
    Dec 20, 2020 · administration of risdiplam. • A clinical pharmacokinetic trial to determine an appropriate dose of risdiplam to minimize toxicity in ...
  33. [33]
    Evrysdi Helps Presymptomatic Infants with Spinal Muscular Atrophy ...
    Aug 27, 2025 · The RAINBOWFISH trial showed that Evrysdi enabled infants to survive without assisted ventilation and achieve motor milestones over 24 months.<|control11|><|separator|>
  34. [34]
    Evaluating Therapeutic Outcomes in Spinal Muscular Atrophy
    Another child who received risdiplam for 6 months remained stable; after receiving gene therapy, the scores improved. Similarly, combining gene therapy with ...
  35. [35]
    New three-year data for Roche's Evrysdi (risdiplam) show long-term ...
    Apr 28, 2022 · New three-year data for Roche's Evrysdi (risdiplam) show long-term improvements in survival and motor milestones in babies with Type 1 spinal muscular atrophy ...Missing: outcomes | Show results with:outcomes
  36. [36]
    Press Releases | Tuesday, Mar 15, 2022 - Genentech
    Mar 15, 2022 · Long-term efficacy data from the pivotal SUNFISH study confirm increases in motor function are sustained at three years while adverse events ...Missing: outcomes | Show results with:outcomes<|separator|>
  37. [37]
    Risdiplam Side Effects: Common, Severe, Long Term - Drugs.com
    Jun 22, 2025 · Very common (10% or more): Upper respiratory tract infection (up to 82%), pneumonia (up to 40%), cough (12.9%), bronchitis (up to 11%) · Common ( ...
  38. [38]
    Risdiplam in Spinal Muscular Atrophy: Safety Profile and Use ... - NIH
    Jan 4, 2024 · The most common AEs were: Respiratory tract infections (35%), gastrointestinal disturbance (20%) and skin and hair abnormalities (10%). Less ...<|control11|><|separator|>
  39. [39]
    Safety of Risdiplam in Japanese Patients with Spinal Muscular Atrophy
    Aug 9, 2025 · About 20.8% of patients experienced side effects, and 1.5% had serious side effects. Common side effects included digestive issues and skin ...
  40. [40]
    Extensively studied, consistent safety profile
    Adverse events occurring in ≥5 infants receiving Evrysdi over 2 years. As of clinical cut-off date: March 27, 2024. *Adverse reactions have an assumed ...
  41. [41]
    [PDF] center for drug evaluation and research - accessdata.fda.gov
    Aug 24, 2020 · The risks associated with the use of risdiplam include retinal toxicity, embryo-fetal toxicity and effects on male fertility. The applicant did ...
  42. [42]
    None
    Nothing is retrieved...<|control11|><|separator|>
  43. [43]
    Comprehensive analysis of adverse events associated with ...
    Elevated liver enzymes, fever, vomiting, and thrombocytopenia were the most common adverse reactions. Most adverse events manifested within the initial month of ...
  44. [44]
    None
    Nothing is retrieved...<|control11|><|separator|>
  45. [45]
  46. [46]
    Search Orphan Drug Designations and Approvals - FDA
    Generic Name: risdiplam. Trade Name: Evrysdi. Date Designated: 01/04/2017. Orphan Designation: Treatment of spinal muscular atrophy.<|control11|><|separator|>
  47. [47]
    NCT04256265 | An Expanded Access Program for Risdiplam in ...
    This expanded access program (EAP) will provide access to risdiplam for eligible participants with Type 1 or Type 2 spinal muscular atrophy (SMA) before it is ...
  48. [48]
    Press Releases | Monday, May 30, 2022 - Genentech
    May 30, 2022 · The FDA Office of Orphan Products Development granted GYM329 Orphan Drug Designation for the treatment of patients with SMA in December 2021.
  49. [49]
    Evrysdi | European Medicines Agency (EMA)
    This product is no longer an orphan medicine. It was originally designated an orphan medicine on 26 February 2019. Evrysdi was withdrawn from the Community ...
  50. [50]
  51. [51]
    Rare disease drug included in medical insurance list - China Daily
    Jan 20, 2023 · Evrysdi, or risdiplam, made by Roche is to treat spinal muscular atrophy (SMA) patients above two-month-old and was approved in June of 2021 ...Missing: date | Show results with:date
  52. [52]
    [PDF] proposal for the addition of risdiplam to the who model
    Nov 1, 2024 · ... risdiplam is expected to be available in a new bioequivalent tablet form, pending FDA approval (anticipated early 2025). The single ...
  53. [53]
  54. [54]
    FDA approves Roche's Evrysdi tablet as first and only tablet for ...
    Evrysdi is the only non-invasive disease-modifying treatment for SMA. The 5 mg Evrysdi tablet can either be swallowed whole or dispersed in water.
  55. [55]
    Page Not Found
    No readable text found in the HTML.<|separator|>
  56. [56]
    Global Risdiplam Compassionate Use Program for Patients with ...
    Roche Position on Pre-Approval Access to Investigational Medicinal Products [Roche website]. 2020. Available at: https://assets.cwp.roche.com/f/126832/x ...
  57. [57]
    WHO Includes Popular Anti-Obesity Drugs On Essential Medicines ...
    Sep 5, 2025 · WHO's 2025 Essential Medicines Lists (EML), published Friday, has ... Risdiplam, produced by Roche, was rejected by the EML expert group.Missing: November | Show results with:November
  58. [58]
    FDA Approves Roche, PTC's SMA Treatment, Evrysdi (Risdiplam)
    Aug 10, 2020 · Evrysdi was provided free of cost to patients who could not be treated with other available drugs for medical or regulatory reasons. Learn more ...Missing: assistance | Show results with:assistance
  59. [59]
    Financial Assistance Options | Evrysdi (risdiplam)
    The Program assists with the cost of the Genentech medicine only. It does not assist with the cost of other medicines, procedures or office visit fees.
  60. [60]
    [PDF] Evrysdi Insurance Policies - Cure SMA
    Evrysdi Insurance Policies. Publicly listed insurance policies for Evrysdi coverage are listed below. Please note that this list.
  61. [61]
    Risdiplam tablets approved at European level - Institut de Myologie
    Already available in the oral solution form, risdiplam (Evrysdi) has now also been authorised at European level in 5 mg tablets.
  62. [62]
    European Commission approves Roche's Evrysdi for babies under ...
    Aug 28, 2023 · The European Commission has approved the extension of the Evrysdi® (risdiplam) European Union (EU) marketing authorisation to include infants with a clinical ...
  63. [63]
    Risdiplam | C22H23N7O | CID 118513932 - PubChem - NIH
    The mechanism of action of risdiplam is as a Survival of Motor Neuron 2 Splicing Modifier, and Multidrug and Toxin Extrusion Transporter 1 Inhibitor, and ...
  64. [64]
    Evrysdi (risdiplam) - Roche
    Evrysdi is an approved treatment for spinal muscular atrophy (SMA) in adults, children and infants from birth.Missing: patient assistance
  65. [65]
  66. [66]
    An expanded access program of risdiplam for patients with Type 1 or ...
    May 14, 2022 · The EAP was designed for eligible patients with Type 1 or 2 SMA prior to commercial availability of risdiplam in the US. The treating physician ...
  67. [67]
    Genentech Evrysdi Co-pay Program
    Eligible commercially insured patients who are prescribed Evrysdi for an FDA-approved use can receive up to $25,000 in assistance per calendar year for drug ...
  68. [68]
    Global Access Program - Roche
    Improving access to healthcare. Global Access Program. Bridging the care gap in low and middle income countries to support global disease elimination goals.Missing: Evrysdi | Show results with:Evrysdi